Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

BRENDA Home
show all | hide all No of entries

Information on EC 1.1.1.267 - 1-deoxy-D-xylulose-5-phosphate reductoisomerase and Organism(s) Plasmodium falciparum and UniProt Accession Q8IKG4

for references in articles please use BRENDA:EC1.1.1.267
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
IUBMB Comments
The enzyme requires Mn2+, Co2+ or Mg2+ for activity, with the first being most effective. The enzyme from several eubacteria, including Escherichia coli, forms part of an alternative nonmevalonate pathway for terpenoid biosynthesis (for diagram, {terp/nonMVA}). The mechanism has been shown to be a retroaldol/aldol reaction .
Specify your search results
Select one or more organisms in this record: ?
This record set is specific for:
Plasmodium falciparum
UNIPROT: Q8IKG4
Show additional data
Do not include text mining results
Include (text mining) results
Include results (AMENDA + additional results, but less precise)
Word Map
The taxonomic range for the selected organisms is: Plasmodium falciparum
The enzyme appears in selected viruses and cellular organisms
Synonyms
1-deoxy-d-xylulose 5-phosphate reductoisomerase, 1-deoxy-d-xylulose-5-phosphate reductoisomerase, 1-deoxy-d-xylulose-5-phosphate, pfdxr, dxp reductoisomerase, mep synthase, cadxr, doxp reductoisomerase, deoxyxylulose 5-phosphate reductoisomerase, mtdxr, more
SYNONYM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
1-deoxy-D-xylulose 5-phosphate reductoisomerase
-
1-deoxy-D-xylulose 5-phosphate isomeroreductase
-
-
-
-
1-deoxy-D-xylulose-5-phosphate reductoisomerase
-
-
1-deoxyxylulose-5-phosphate reductoisomerase
-
2-C-methyl-D-erythritol 4-phosphate synthase
-
-
-
-
deoxyxylulose 5-phosphate reductoisomerase
-
-
-
-
DOXP-reductoisomerase
-
-
DXP reductoisomerase
-
-
-
-
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
2-C-methyl-D-erythritol 4-phosphate + NADP+ = 1-deoxy-D-xylulose 5-phosphate + NADPH + H+
show the reaction diagram
highly conserved active site structure, active site residues Asp157, Glu159, and Glu241, residue His219 is essential for placing the substrate in the active site for optimal catalysis
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
redox reaction
-
-
-
-
oxidation
-
-
-
-
reduction
-
-
-
-
SYSTEMATIC NAME
IUBMB Comments
2-C-methyl-D-erythritol-4-phosphate:NADP+ oxidoreductase (isomerizing)
The enzyme requires Mn2+, Co2+ or Mg2+ for activity, with the first being most effective. The enzyme from several eubacteria, including Escherichia coli, forms part of an alternative nonmevalonate pathway for terpenoid biosynthesis (for diagram, {terp/nonMVA}). The mechanism has been shown to be a retroaldol/aldol reaction [2].
CAS REGISTRY NUMBER
COMMENTARY hide
210756-42-6
-
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
1-deoxy-D-xylulose 5-phosphate + NADPH + H+
2-C-methyl-D-erythritol 4-phosphate + NADP+
show the reaction diagram
1-deoxy-D-xylulose 5-phosphate + NADPH + H+
2-C-methyl-D-erythritol 4-phosphate + NADP+
show the reaction diagram
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
1-deoxy-D-xylulose 5-phosphate + NADPH + H+
2-C-methyl-D-erythritol 4-phosphate + NADP+
show the reaction diagram
1-deoxy-D-xylulose 5-phosphate + NADPH + H+
2-C-methyl-D-erythritol 4-phosphate + NADP+
show the reaction diagram
COFACTOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
NADP+
NADPH
NADPH
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Mg2+
active site divalent metal ion
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(2R)-3-[4-(hydroxymethyl)-4-[[4-(hydroxymethyl)phenyl]methyl]piperidin-1-yl]propane-1,2-diol
-
-
(2R)-3-[4-[2-[(cyclohexa-2,4-dien-1-yl)oxy]ethyl]-4-(hydroxymethyl)piperidin-1-yl]propane-1,2-diol
-
-
(2R)-3-[[[1-butyl-2-(cyclobutylmethanesulfonyl)-1H-imidazol-5-yl]methyl](methyl)amino]propane-1,2-diol
-
-
(3R)-1-(2,2-dimethylpropyl)-3-hydroxy-3-([[(5-methyl-4H-1,2,4-triazol-3-yl)methyl]amino]methyl)piperidin-2-one
-
-
(3S)-1-(cyclopropylmethyl)-3-([[(4,5-dimethyl-1,3-thiazol-2-yl)methyl]amino]methyl)-3-hydroxypiperidin-2-one
-
-
(3S,4R)-3-((2S)-1-(6,7-dimethoxy-4-(pyrrolidin-1-yl)-1,7,8,8a-tetrahydroquinazolin-2-yl)-4-hydroxybutan-2-yl)-4-hydroxytetrahydrothiophene 1,1-dioxide
-
-
(4-chloro-2-[[1-(2,3-dihydroxypropyl)piperidin-4-yl]oxy]phenyl)(piperidin-1-yl)methanone
-
-
(5R)-5-[1-[(2R)-2,3-dihydroxypropyl]piperidin-4-yl]-5-(3-phenylpropyl)imidazolidine-2,4-dione
-
-
([[acetyl(hydroxy)amino]methoxy]methyl)phosphonic acid
-
-
([[formyl(hydroxy)amino]methoxy]methyl)phosphonic acid
-
-
1-[(2S)-2,3-dihydroxypropyl]-N-[3-(furan-2-yl)phenyl]piperidine-4-carboxamide
-
-
3,3-dimethyl-11-phenyl-2,3,4,5,10,11-hexahydro-1H-dibenzo[b,e][1,4]diazepin-1-one
-
4-(1-(4-hydroxy-2-oxo-2H-chromen-3-yl)-2-methylpropyl)-5-methyl-2-(4-nitrophenyl)-1,2-dihydro-3H-pyrazol-3-one
-
-
4-butyl-6-[4-([[(2R)-2,3-dihydroxypropyl](methyl)amino]methyl)phenyl]pyridin-2(1H)-one
-
-
diethyl [2-(3-hydroxyanilino)-2-oxoethyl]phosphonate
45.2% inhibition at 0.25 mM
diethyl [2-[3-(hydroxymethyl)anilino]-2-oxoethyl]phosphonate
40.7% inhibition at 0.25 mM
-
ethyl 1-[(2R)-2,3-dihydroxypropyl]-4-(2-phenoxyethyl)piperidine-4-carboxylate
-
-
ethyl 1-[(2R)-2,3-dihydroxypropyl]-4-[[2-(trifluoromethyl)phenyl]methyl]piperidine-4-carboxylate
-
-
ethyl 2-(2-ethoxy-2-oxoethyl)-2,5-dihydro-1H-benzo[b][1,4]diazepine-3-carboxylate
-
fosmidomycin
methyl N-([(3S)-1-[(2,3-difluorophenyl)methyl]-3-hydroxy-2-oxopiperidin-3-yl]methyl)glycinate
-
-
[(3,4-dichlorophenyl)([2-[hydroxy(methyl)amino]-2-oxoethyl]sulfanyl)methyl]phosphonic acid
-
-
[1-(3,4-dichlorophenyl)-3-[formyl(hydroxy)amino]propyl]phosphonic acid
inhibition of strain D2d
[2-([1-[(2R)-2,3-dihydroxypropyl]piperidin-4-yl]oxy)phenyl](piperidin-1-yl)methanone
-
-
[3-[acetyl(hydroxy)amino]-1-(1,4-dihydropyridin-4-yl)propyl]phosphonic acid
-
-
[3-[acetyl(hydroxy)amino]-1-(3,4-dichlorophenyl)propyl]phosphonic acid
inhibition of strain D2d
[4-(2-acetylanilino)-4-oxobutyl]phosphonic acid
-
-
[4-(2-fluoroanilino)-4-oxobutyl]phosphonic acid
-
-
[4-[2-(methanesulfonyl)anilino]-4-oxobutyl]phosphonic acid
-
-
(4-[[3-(hydroxymethyl)phenyl]amino]-4-oxobutyl)phosphonic acid
-
-
3-(hydroxy([(2-phenylbutanoyl)amino]acetyl)amino)propylphosphonic acid
-
-
3-(hydroxy([(3-methylbutanoyl)amino]acetyl)amino)propylphosphonic acid
-
-
3-(hydroxy([(4-phenoxybutanoyl)amino]acetyl)amino)propylphosphonic acid
-
-
3-(hydroxy([(4-phenylbutanoyl)amino]acetyl)amino)propylphosphonic acid
-
-
3-[(([(3,4-dimethoxyphenyl)acetyl]amino)acetyl)(hydroxy)amino]propylphosphonic acid
-
-
3-[([(cyclopropylcarbonyl)amino]acetyl)(hydroxy)amino]propylphosphonic acid
-
-
3-[hydroxy(([3-(trifluoromethoxy)benzoyl]amino)acetyl)amino]propylphosphonic acid
-
-
3-[hydroxy(([4-(1H-indol-3-yl)butanoyl]amino)acetyl)amino]propylphosphonic acid
-
-
diethyl (2-[[3-(hydroxymethyl)phenyl]amino]-2-oxoethyl)phosphonate
-
-
diethyl [2-[(3-cyanophenyl)amino]-2-oxoethyl]phosphonate
-
-
diethyl [2-[(3-hydroxyphenyl)amino]-2-oxoethyl]phosphonate
-
-
fosmidomycin
FR-900098
-
fosmidomycin homologue
FR900098
[2-[(3-bromophenyl)amino]-2-oxoethyl]phosphonic acid
-
-
[2-[(3-hydroxyphenyl)amino]-2-oxoethyl]phosphonic acid
-
-
[2-[(3-methoxyphenyl)amino]-2-oxoethyl]phosphonic acid
-
-
[3-[acetyl(hydroxy)amino]-1-(pyridin-3-yl)propyl]phosphonic acid
-
[3-[acetyl(hydroxy)amino]-1-(pyridin-4-yl)propyl]phosphonic acid
-
[3-[acetyl(hydroxy)amino]-1-phenylpropyl]phosphonic acid
-
[3-[formyl(hydroxy)amino]-1-(pyridin-3-yl)propyl]phosphonic acid
-
[3-[formyl(hydroxy)amino]-1-(pyridin-4-yl)propyl]phosphonic acid
-
[3-[formyl(hydroxy)amino]-1-phenylpropyl]phosphonic acid
-
[4-[(3-bromophenyl)amino]-4-oxobutyl]phosphonic acid
-
-
[4-[(3-hydroxyphenyl)amino]-4-oxobutyl]phosphonic acid
-
-
additional information
-
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.000021
fosmidomycin
pH 7.5, 22°C
0.0000019
[3-[acetyl(hydroxy)amino]-1-(pyridin-3-yl)propyl]phosphonic acid
pH 7.5, 22°C
0.000013
[3-[acetyl(hydroxy)amino]-1-(pyridin-4-yl)propyl]phosphonic acid
pH 7.5, 22°C
0.000085
[3-[acetyl(hydroxy)amino]-1-phenylpropyl]phosphonic acid
pH 7.5, 22°C
0.000013
[3-[formyl(hydroxy)amino]-1-(pyridin-3-yl)propyl]phosphonic acid
pH 7.5, 22°C
0.0000089
[3-[formyl(hydroxy)amino]-1-(pyridin-4-yl)propyl]phosphonic acid
pH 7.5, 22°C
0.00048
[3-[formyl(hydroxy)amino]-1-phenylpropyl]phosphonic acid
pH 7.5, 22°C
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.00036
([[acetyl(hydroxy)amino]methoxy]methyl)phosphonic acid
Plasmodium falciparum
pH and temperature not specified in the publication
-
0.0049
([[formyl(hydroxy)amino]methoxy]methyl)phosphonic acid
Plasmodium falciparum
pH and temperature not specified in the publication
-
0.00312 - 0.125
3,3-dimethyl-11-phenyl-2,3,4,5,10,11-hexahydro-1H-dibenzo[b,e][1,4]diazepin-1-one
-
0.1
4-(1-(4-hydroxy-2-oxo-2H-chromen-3-yl)-2-methylpropyl)-5-methyl-2-(4-nitrophenyl)-1,2-dihydro-3H-pyrazol-3-one
Plasmodium falciparum
pH 7.5, 22°C
-
0.04 - 0.125
ethyl 2-(2-ethoxy-2-oxoethyl)-2,5-dihydro-1H-benzo[b][1,4]diazepine-3-carboxylate
-
0.000036
fosmidomycin
Plasmodium falciparum
pH and temperature not specified in the publication
0.000018
FR-900098
Plasmodium falciparum
pH and temperature not specified in the publication
0.0000045
[(3,4-dichlorophenyl)([2-[hydroxy(methyl)amino]-2-oxoethyl]sulfanyl)methyl]phosphonic acid
Plasmodium falciparum
pH and temperature not specified in the publication
-
0.000028
[1-(3,4-dichlorophenyl)-3-[formyl(hydroxy)amino]propyl]phosphonic acid
Plasmodium falciparum
pH and temperature not specified in the publication
0.00009
[3-[acetyl(hydroxy)amino]-1-(3,4-dichlorophenyl)propyl]phosphonic acid
Plasmodium falciparum
pH and temperature not specified in the publication
0.064
[4-(2-acetylanilino)-4-oxobutyl]phosphonic acid, [4-(2-fluoroanilino)-4-oxobutyl]phosphonic acid, [4-[2-(methanesulfonyl)anilino]-4-oxobutyl]phosphonic acid
Plasmodium falciparum
above, pH and temperature not specified in the publication
-
0.0093
3-(hydroxy([(2-phenylbutanoyl)amino]acetyl)amino)propylphosphonic acid
Plasmodium falciparum
-
-
0.0096
3-(hydroxy([(3-methylbutanoyl)amino]acetyl)amino)propylphosphonic acid
Plasmodium falciparum
-
-
0.0004
3-(hydroxy([(4-phenoxybutanoyl)amino]acetyl)amino)propylphosphonic acid
Plasmodium falciparum
-
-
0.02
3-(hydroxy([(4-phenylbutanoyl)amino]acetyl)amino)propylphosphonic acid
Plasmodium falciparum
-
-
0.012
3-[(([(3,4-dimethoxyphenyl)acetyl]amino)acetyl)(hydroxy)amino]propylphosphonic acid
Plasmodium falciparum
-
-
0.0033
3-[([(cyclopropylcarbonyl)amino]acetyl)(hydroxy)amino]propylphosphonic acid
Plasmodium falciparum
-
-
0.0029
3-[hydroxy(([3-(trifluoromethoxy)benzoyl]amino)acetyl)amino]propylphosphonic acid
Plasmodium falciparum
-
-
0.0066
3-[hydroxy(([4-(1H-indol-3-yl)butanoyl]amino)acetyl)amino]propylphosphonic acid
Plasmodium falciparum
-
-
0.000032 - 0.00117
fosmidomycin
0.000018
FR-900098
Plasmodium falciparum
-
-
0.118
FR900098
Plasmodium falciparum
-
0.00031 - 0.00044
[3-[acetyl(hydroxy)amino]-1-(pyridin-3-yl)propyl]phosphonic acid
0.00046 - 0.00063
[3-[acetyl(hydroxy)amino]-1-(pyridin-4-yl)propyl]phosphonic acid
0.0017 - 0.0035
[3-[acetyl(hydroxy)amino]-1-phenylpropyl]phosphonic acid
0.00018 - 0.00034
[3-[formyl(hydroxy)amino]-1-(pyridin-3-yl)propyl]phosphonic acid
0.00017 - 0.00018
[3-[formyl(hydroxy)amino]-1-(pyridin-4-yl)propyl]phosphonic acid
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
7.5
-
assay at
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
22
assay at room temperature
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
malfunction
DXR is essential for the survival of the pathogen, and its inhibition leads to the antimalarial action
metabolism
1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) catalyzes the second step of the nonmevalonate (or MEP) pathway that functions in several organisms and plants for the synthesis of isoprenoids
physiological function
DXR is essential for the survival of multiple pathogenic bacteria/parasites, including those that cause tuberculosis and malaria in humans
metabolism
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
47000
-
x * 47000, SDS-PAGE
63000
-
gel filtration
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
?
-
x * 47000, SDS-PAGE
additional information
CRYSTALLIZATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
generation of homology model and ligand docking studies
hanging-drop vapour-diffusion method in the presence of NADPH, data to 1.85 A resolution. Space group C2
-
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
H219Q
site-directed mutagenesis, the mutation decreased the affinity toward the substrate 1-deoxy-D-xylulose 5-phosphate with an 8-fold increase in the Km compared to the wild-type enzyme
STORAGE STABILITY
ORGANISM
UNIPROT
LITERATURE
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
by immobilized metal affinity chromatography on a Co column, ca. 90% pure
-
recombinant His-tagged enzyme by nickkel affinity chromatography and gel filtration
-
recombinant protein
-
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
expression in Escherichia coli
-
into the pQE31 expression vector resulting in an amino-terminal His6 fusion
-
recombinant expression of His-tagged enzyme
-
APPLICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
drug development
enzyme DXR is an antimicrobial target
drug development
medicine
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Wiesner, J.; Hintz, M.; Altincicek, B.; Sanderbrand, S.; Weidemeyer, C.; Beck, E.; Jomaa, H.
Plasmodium falciparum: Detection of the deoxyxylulose 5-phosphate reductoisomerase activity
Exp. Parasitol.
96
182-186
2000
Plasmodium falciparum
Manually annotated by BRENDA team
Singh, N.; Cheve, G.; Avery, M.A.; McCurdy, C.R.
Comparative protein modeling of 1-deoxy-D-xylulose-5-phosphate reductoisomerase enzyme from Plasmodium falciparum: a potential target for antimalarial drug discovery
J. Chem. Inf. Model.
46
1360-1370
2006
Plasmodium falciparum (O96693), Plasmodium falciparum
Manually annotated by BRENDA team
Tahar, R.; Basco, L.K.
Molecular epidemiology of malaria in Cameroon. XXV. In vitro activity of fosmidomycin and its derivatives against fresh clinical isolates of Plasmodium falciparum and sequence analysis of 1-deoxy-D-xylulose 5-phosphate reductoisomerase
Am. J. Trop. Med. Hyg.
77
214-220
2007
Plasmodium falciparum (O96693), Plasmodium falciparum
Manually annotated by BRENDA team
Giessmann, D.; Heidler, P.; Haemers, T.; Van Calenbergh, S.; Reichenberg, A.; Jomaa, H.; Weidemeyer, C.; Sanderbrand, S.; Wiesner, J.; Link, A.
Towards new antimalarial drugs: synthesis of non-hydrolyzable phosphate mimics as feed for a predictive QSAR study on 1-deoxy-D-xylulose-5-phosphate reductoisomerase inhibitors
Chem. Biodivers.
5
643-656
2008
Escherichia coli, Plasmodium falciparum
Manually annotated by BRENDA team
Umeda, T.; Tanaka, N.; Kusakabe, Y.; Nakanishi, M.; Kitade, Y.; Nakamura, K.T.
Crystallization and preliminary X-ray crystallographic study of 1-deoxy-D-xylulose 5-phosphate reductoisomerase from Plasmodium falciparum
Acta Crystallogr. Sect. F
66
330-332
2010
Plasmodium falciparum
Manually annotated by BRENDA team
Goble, J.L.; Adendorff, M.R.; de Beer, T.A.; Stephens, L.L.; Blatch, G.L.
The malarial drug target Plasmodium falciparum 1-deoxy-D-xylulose-5-phosphate reductoisomerase (PfDXR): development of a 3-D model for identification of novel, structural and functional features and for inhibitor screening
Protein Pept. Lett.
17
109-120
2010
Plasmodium falciparum (Q8IKG4), Plasmodium falciparum
Manually annotated by BRENDA team
Xue, J.; Diao, J.; Cai, G.; Deng, L.; Zheng, B.; Yao, Y.; Song, Y.
Antimalarial and structural studies of pyridine-containing inhibitors of 1-deoxyxylulose-5-phosphate reductoisomerase
ACS Med. Chem. Lett.
4
278-282
2013
Escherichia coli, Plasmodium falciparum (O96693), Plasmodium falciparum
Manually annotated by BRENDA team
Bodill, T.; Conibear, A.C.; Mutorwa, M.K.; Goble, J.L.; Blatch, G.L.; Lobb, K.A.; Klein, R.; Kaye, P.T.
Exploring DOXP-reductoisomerase binding limits using phosphonated N-aryl and N-heteroarylcarboxamides as DXR inhibitors
Bioorg. Med. Chem.
21
4332-4341
2013
Escherichia coli, Plasmodium falciparum
Manually annotated by BRENDA team
Kesharwani, S.; Sundriyal, S.
Non-hydroxamate inhibitors of 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXR) a critical review and future perspective
Eur. J. Med. Chem.
213
113055
2021
Escherichia coli (P45568), Mycobacterium tuberculosis (P9WNS1), Plasmodium falciparum (Q8IKG4), Mycobacterium tuberculosis H37Rv (P9WNS1), Mycobacterium tuberculosis ATCC 25618 (P9WNS1)
Manually annotated by BRENDA team
Sharma, D.; Dada, R.; Tejavath, K.; Rai, P.; Soni, R.; Yaragorla, S.; Bhatt, T.
A paradigm towards the antimalarial quest in silico identification and biological evaluation of novel inhibitors targeting 1-deoxy-D-xylulose-5-phosphate reductoisomerase
J. Biomol. Struct. Dyn.
38
295-301
2020
Plasmodium falciparum (Q8IKG4)
Manually annotated by BRENDA team
Wadood, A.; Ghufran, M.; Hassan, S.; Khan, H.; Azam, S.; Rashid, U.
In silico identification of promiscuous scaffolds as potential inhibitors of 1-deoxy-D-xylulose 5-phosphate reductoisomerase for treatment of falciparum malaria
Pharm. Biol.
55
19-32
2017
Plasmodium falciparum (Q8IKG4), Plasmodium falciparum
Manually annotated by BRENDA team